Source comparison
Thymosin Alpha-1 Contraindications: Safety Profile Comparison
Th1-Dominant Autoimmune Disease Tα1 upregulates IFN-γ and IL-2, amplifying pathogenic Th1 responses Relative—dose and timing dependent Moderate (systematic reviews, animal models) Baseline Th1/Th2 cytokine profiling; exclude if IFN-γ >150 pg/mL Pregnancy/Lacta
This comparison does not assign a generated winner or score.
- Th1-Dominant Autoimmune Disease
- Tα1 upregulates IFN-γ and IL-2, amplifying pathogenic Th1 responses
- Relative—dose and timing dependent
- Moderate (systematic reviews, animal models)
- Baseline Th1/Th2 cytokine profiling; exclude if IFN-γ >150 pg/mL
- Pregnancy/Lactation
- Unknown fetal transfer; potential disruption of maternal immune tolerance
- Absolute—insufficient safety data
- Low (animal studies only, no human data)
- Mandatory pregnancy testing; exclude all pregnant/nursing subjects
- Known Hypersensitivity
- IgE-mediated or T-cell mediated allergic reaction to peptide or excipients
- Absolute—anaphylaxis risk
- High (case reports, documented incidence)
- Pre-screening allergy history; intradermal skin testing if prior reactions
- Severe Immunodeficiency (AIDS, chemotherapy)
- T-cell expansion could trigger cytokine release syndrome or immune reconstitution inflammatory syndrome
- Relative—depends on CD4+ count and viral load
- Moderate (case series, immunology theory)
- Exclude if CD4+ <200 cells/μL; delay until immune reconstitution complete
- Active Malignancy with Immune Escape
- Tα1 may enhance tumor-specific immunity or inadvertently support immune evasion depending on tumor microenvironment
- Conditional—tumor type specific
- Low (conflicting evidence, mechanism unclear)
- Avoid in melanoma and renal cell carcinoma; consider in hepatocellular carcinoma with oncology oversight